F Penault-Llorca, F Dalenc, S Chabaud, P Cottu, D Allouache, D Cameron, J Grenier, L Venat Bouvet, A Jegannathen, M Campone, M Debled, A-C Hardy-Bessard, S Giacchetti, P Barthelemy, L Kaluzinski, A Mailliez, M-A Mouret-Reynier, E Legouffe, A Cayre, M Martinez, C Delbaldo, D Mollon-Grange, E J Macaskill, M Sephton, L Stefani, B Belgadi, M Winter, H Orfeuvre, M Lacroix-Triki, H Bonnefoi, J Bliss, J-L Canon, J Lemonnier, F Andre, T Bachelot
BACKGROUND: The purpose of this study was to evaluate the prognostic value of the multigene EndoPredict test in prospectively collected data of patients screened for the randomized, double-blind, phase III UNIRAD trial, which evaluated the addition of everolimus to adjuvant endocrine therapy in high-risk, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. PATIENTS AND METHODS: Patients were classified into low or high risk according to the EPclin score, consisting of a 12-gene molecular score combined with tumor size and nodal status...
April 30, 2024: ESMO Open